about
The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translationSLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant gliomaReproductive factors and risk of primary brain tumors in womenEarly life exposures and the risk of adult gliomaAnthropometric factors in relation to risk of gliomaSSBP2 variants are associated with survival in glioblastoma patientsTimed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.Medical decision-making capacity in patients with malignant gliomaPhase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaPhase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBMSurvival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).Brain tumor risk according to germ-line variation in the MLLT10 locus.Cognition in patients with newly diagnosed brain metastasis: profiles and implications.The RNA-binding protein HuR promotes glioma growth and treatment resistance.Cancer susceptibility variants and the risk of adult glioma in a US case-control study.Growth factor dependent regulation of centrosome function and genomic instability by HuR.Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomasPhase I trial of sorafenib in patients with recurrent or progressive malignant glioma.Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE studyPhase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.Capacity of patients with brain metastases to make treatment decisionsPhosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function.Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcomePrediagnostic body weight and survival in high grade glioma.Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Toenail iron, genetic determinants of iron status, and the risk of gliomaCircadian pathway genes in relation to glioma risk and outcome.
P50
Q24794247-14A3DD2B-971D-4BEE-8289-269BB8EFB0A2Q27325399-C1919344-AEB7-4614-B829-4627401A3EB3Q28387379-A671D277-96E0-4592-BB77-B6CE5C48A1D3Q28389459-C5A40491-451C-44C6-87E5-0495065BED02Q28397195-1F588E4A-03A0-40F9-90FB-7E3CE8B61CBEQ28943446-D8BE7A93-4695-4630-A03A-40782A2E56DAQ30252736-261EFF79-B9E5-4F02-8D48-5397A0F9F11CQ30493510-93C03397-0675-44FE-8548-5D1EF428DACCQ30661157-7E93ACB8-5446-40EF-8DB3-05057EB4575AQ33375093-27371753-9ADE-4CDC-8FCF-DAB46C6349A5Q33380081-F82CC596-3583-47C0-B152-E406EADC542DQ33417361-4558DD30-C163-4FC2-AB34-AB0B16366912Q33587028-7EFDC76D-2B71-417F-AD5D-DDC85F88D4E8Q33712977-70DAF719-AE9C-4F2A-AC54-72E980713CCEQ33819663-89346C48-6D35-4B29-9BC4-AB86654C96FCQ33824979-39B5D254-4ECF-4B98-9AFB-0FF848700EB9Q34269566-DCA05E93-CA82-4152-9EE3-C56CDB4EEA7DQ34389144-1F70F737-D083-434A-AC57-AE14EBE05DA9Q34537960-85D9C3DD-B721-43C2-B18E-58454046029AQ34705193-2166175B-F20F-4ED6-AC07-51C68AAC321EQ34972626-0D81A9C6-B9A3-47BA-9F6B-61D1AD69ECF1Q34988117-9366C1B9-21D5-4E1E-8FB1-53B369785436Q35112916-04B4CC4C-CFAF-467C-93BF-6A5A88C62D08Q35255512-44EBC48D-E0F4-4F94-84E8-6DD8D799EEF7Q35403440-C7787338-A1AD-4D4A-AD86-B64AC4148199Q35570274-1189D9BE-6478-47C9-BCA1-7072DE0AAED3Q35788615-F154CBB6-F3F2-4CD2-9B7A-4F3B5E5670F7Q35800712-32F9B92C-86C2-41EE-9F69-1FE053810D57Q35883334-CFD2C60C-5C0A-40C3-9C66-F9866BB48EF9Q36234835-F59023C8-B531-43FD-9FC4-C80F2562102FQ36449211-D912FCB1-A126-4CCB-9131-4213FBBD5244Q36713494-532C2D27-0733-4FA2-BC29-B2D1733B114CQ36871155-FDE32E68-776D-47B5-9A6C-FC800AED121DQ36908133-77B08954-F379-418E-9F90-00A75FB284AFQ36920373-014B62C5-CFDD-4C7F-9009-AA3DBE179F16Q37046781-E4C572BD-25E7-4CC1-B4C3-855A586BD057Q37060466-2C0BB622-58B1-402F-B1D4-7ABF6F6F2A23Q37064326-97D1BAA9-53C6-4835-8AA2-046E8C757CB3Q37297023-F36C715E-6DCF-43F8-926C-C8A1FDE90F21Q37626221-F8DF6F6B-99A0-4A5F-9995-648338990A17
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Louis B Nabors
@ast
Louis B Nabors
@en
Louis B Nabors
@es
Louis B Nabors
@nl
type
label
Louis B Nabors
@ast
Louis B Nabors
@en
Louis B Nabors
@es
Louis B Nabors
@nl
prefLabel
Louis B Nabors
@ast
Louis B Nabors
@en
Louis B Nabors
@es
Louis B Nabors
@nl
P106
P1153
24778375400
P31
P496
0000-0001-5926-2230